Pregabalin Capsule
Product Images NDC 13668-361

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 13668-361). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg (100mg)

Label for Pregabalin capsules 100 mg by Torrent Pharmaceuticals Limited, containing 30 capsules per bottle. The label includes storage instructions, manufacturer information, and the statement Rx only, indicating prescription use. NDC number 13668-361 is visible.*

FDA Label Image

150mg (150mg)

Label for Pregabalin Capsules 150 mg by Torrent Pharmaceuticals Limited. The label indicates a 30-capsule package with dosing instructions and storage conditions. It includes warnings to keep out of reach of children and pharmacist dispensing instructions, along with manufacturer and distributor information and barcodes.*

FDA Label Image

200mg (200mg)

Pregabalin Capsules 200 mg oral capsule label showing a bottle containing 30 capsules. The label includes storage instructions, manufacturer details (Torrent Pharmaceuticals Limited), and cautions such as keeping out of reach of children and dispensing with a child-resistant closure. Marked Rx only with a National Drug Code (NDC) 13668-363-30.*

FDA Label Image

225mg (225mg)

Label for Pregabalin Capsules 225 mg by Torrent Pharmaceuticals Limited. The label indicates 30 capsules per container, with storage instructions and a child-resistant closure. It includes the NDC number 13668-364-30 and emphasizes dispensing with an accompanying medication guide. The label has a barcode and warnings to keep out of reach of children.*

FDA Label Image

25mg (25mg)

Pregabalin Capsules 25 mg oral capsule label showing a package size of 30 capsules. Manufactured by Torrent Pharmaceuticals Limited, the label includes storage instructions, dosage information, and a note to dispense the Medication Guide. The label features the NDC 13668-358-30 and highlights that the capsules require a prescription (Rx only).*

FDA Label Image

300mg (300mg)

Pregabalin Capsules 300 mg oral capsule label from Torrent Pharmaceuticals Limited. The label indicates a package of 30 capsules with storage instructions and warnings about keeping out of reach of children. It includes the NDC number 13668-365-30 and directions to dispense the medication guide to each patient. The label also shows the manufacturer information for Torrent Pharmaceuticals Ltd, India.*

FDA Label Image

50mg (50mg)

Pregabalin Capsules 50 mg oral capsule label for a 30-capsule bottle by Torrent Pharmaceuticals Limited. The label includes dosage instructions, storage conditions, and regulatory information. It features the product name, strength, quantity, NDC 13668-359-30, and cautions to keep out of reach of children.*

FDA Label Image

75mg (75mg)

Label for Pregabalin Capsules 75 mg, containing 30 capsules per package. The label includes storage instructions, dosage warnings, and manufacturer information for Torrent Pharmaceuticals Limited. It also features the NDC 13668-360-30, pharmacist dispensing instructions, and indicates the product is prescription-only.*

FDA Label Image

Image (9b61995b 06b7 40e3 B8cb 0e649ffbb2e6 269 2)

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 01)

This image shows a formula used to calculate creatinine clearance (CLCr), which factors in age, weight, and serum creatinine levels, including an adjustment multiplier for female patients. It is part of a drug facts or clinical calculation text panel.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 02)

Chemical structure diagram of pregabalin, showing its molecular formula with labeled functional groups including a carboxylic acid (CO2H) and an amino group (NH2).*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents percent of patients improved.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 04)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It shows two curves representing Pregabalin 100 mg three times a day and placebo, indicating differences in patient pain improvement over a range of values.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 05)

A line graph displaying percent improvement in pain from baseline against percent of patients improved. It compares Pregabalin oral capsules at strengths 300 mg, 150 mg, and 75 mg taken twice daily with placebo, showing the relative efficacy over a range of pain improvement percentages.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 06)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. Three lines represent Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends in patient pain improvement over a range of percentages.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 07)

A Kaplan-Meier curve chart showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg taken three times a day, Pregabalin 50 mg taken three times a day, and a placebo group. Two vertical lines highlight specific percent improvement thresholds around 30% and 50% pain improvement.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 08)

A bar chart depicting reported rates (%) from studies E1 and E3 comparing placebo and various doses of pregabalin. Study E1 shows increasing reported rates with dose increments from 50 mg/day to 600 mg/day, labeled with sample sizes. Study E3 presents reported rates for placebo, 600 mg/day pregabalin, and a third unlabelled group. The chart includes a note indicating statistical significance versus placebo.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 09)

A line graph showing seizure reduction median percentage change from baseline versus dose in mg/day for Pregabalin. Four study series (E1BD, E2TID, E3BD, E3TID) are represented by different symbols. Data points indicate dose-response trends with associated p-values for statistical significance.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 10)

A vertical bar chart showing responder rates (%) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rate is approximately 22.6% for Placebo, 29.1% for 2.5 mg/kg/day, and 40.6% for 10 mg/kg/day, with subject counts 93, 103, and 96 respectively shown below each group on the x-axis.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 12)

A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR over a 180-day period, comparing Pregabalin and Placebo groups. The graph illustrates a higher survival rate without LTR in the Pregabalin group compared to the Placebo group over time.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 13)

A line graph comparing the percent of subjects improved over time from baseline to week 12, using the BOCF method, for Pregabalin versus Placebo. The x-axis represents percent improvement from baseline to week 12, and the y-axis shows the percent of subjects improved. Two lines show Pregabalin consistently having a higher percentage of subjects improved than Placebo.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 14)

A line graph comparing the percentage of subjects improved over time from baseline to Week 16 using the Brief Opioid Cessation Function (BOCF) for Pregabalin versus Placebo. The x-axis shows percent improvement, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin and Placebo.*

FDA Label Image

Image (C3bcdf74 0ed9 439b 8f44 3f07e5c04e46 15)

FDA Label Image

Image (Figure 9)

A line graph depicting survival or event rates over time for different groups distinguished by line style or color. The vertical axis represents percentage values from 0 to 100, while the horizontal axis shows time progressing from left to right. Multiple lines trend downward, indicating decreasing percentages as time increases.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.